CagriSema: Cagrilintide and Semaglutide
CagriSema is Novo Nordisk's once-weekly combination of cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 drug in Ozempic and Wegovy. It is under FDA review for chronic weight management and is not approved.
2 compounds · Under FDA review, not approved · Reviewed
CagriSema is not FDA-approved. This page describes CagriSema only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer
FDA status
Cagrilintide: Neither cagrilintide nor CagriSema is FDA-approved as of November 2026. Novo Nordisk submitted a New Drug Application for CagriSema for chronic weight management in December 2025 and has said it expects an FDA decision in the fourth quarter of 2026. FDA has stated that cagrilintide cannot be used in compounding under federal law, so any product sold now as cagrilintide or CagriSema is not FDA-reviewed.
Semaglutide: Approved in several forms. Ozempic injection is approved for type 2 diabetes. Wegovy injection is approved for chronic weight management, and a higher-strength version, Wegovy HD, was approved in March 2026. A Wegovy pill was approved in December 2025 for weight management and for lowering cardiovascular risk. Oral tablets for type 2 diabetes are sold as Rybelsus and, since February 2026, under the Ozempic name.
Evidence
Cagrilintide: Large phase 3 trials exist. In REDEFINE 1 (published in NEJM in 2025), adults with obesity on CagriSema lost about 20% of body weight at 68 weeks versus 3% on placebo; in a 2026 head-to-head trial CagriSema did not meet its goal of matching tirzepatide. Data on cagrilintide alone come mostly from phase 2 and the comparison arms of these trials.
Semaglutide: Large, long human trials. Average weight loss in the STEP 1 trial was about 15%.
Risks
Cagrilintide: The most common side effects in trials were nausea, vomiting, diarrhea and constipation, which are typical of drugs that slow digestion. Because it is combined with semaglutide, CagriSema would be expected to carry semaglutide's warnings, including its boxed warning on thyroid C-cell tumors, but no label exists yet. Unapproved products sold online carry unknown purity and dose. WADA does not name cagrilintide; as a substance with no government approval for human use it may fall under S0 (non-approved substances), while semaglutide itself is not prohibited.
Semaglutide: The label carries a boxed warning about thyroid C-cell tumors, based on rodent studies. It is not known whether the same happens in people. The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain. Labels for this class also warn about pancreatitis.
Sport
Cagrilintide: WADA does not name cagrilintide; as a substance with no government approval for human use it may fall under S0 (non-approved substances), while semaglutide itself is not prohibited.
Semaglutide: It is not on the 2026 WADA Prohibited List.
Related
Each compound has its own profile: Cagrilintide, Semaglutide. See also the Wolverine blend and the 2026 regulatory tracker.
Questions
What is in CagriSema?
Cagrilintide and Semaglutide.
Is CagriSema FDA-approved?
No. Novo Nordisk has applied to FDA for chronic weight management, and no decision had been announced when this page was reviewed.
Sources: FDA: Concerns with unapproved GLP-1 drugs used for weight loss; Novo Nordisk Form 6-K, H1 2026 financial report (SEC); PubMed: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2); ACC journal scan: REDEFINE 1 and REDEFINE 2; Managed Healthcare Executive: GLP-1 pills; Prime Therapeutics: GLP-1 pipeline update, August 2026; Novo Nordisk: Wegovy and Saxenda safety information; Polsinelli: FDA compounded GLP-1 policy; WADA: 2026 Prohibited List.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.